Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Overview | Management | Board of Directors | Strategic Alliances | Partnering | Contact Us
    About Anacor

We are a biopharmaceutical company developing small molecule therapeutics derived from our boron chemistry platform Learn more about Kerydin
Learn more about AN2728


Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We have discovered, synthesized and developed eight product candidates currently in development. Our two lead product candidates are topically administered dermatologic compounds-Kerydin™ (formerly AN2690), a topical antifungal for the potential treatment of mild-to-moderate onychomycosis, and AN2728 a topical anti-inflammatory for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. In addition to our two lead programs, we have discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to Kerydin and AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK ‘052), an investigational antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. We have discovered three other compounds that we have out-licensed for further development — one compound is licensed to Eli Lilly and Company for the potential treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for the potential treatment of human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for development in tuberculosis (TB). In addition, we have a pipeline of internally developed topical and systemic boron- based compounds in development.



  • Anacor was founded based on technology created by board members and scientific advisory board co-chairs, Dr. Lucy Shapiro at Stanford University and Dr. Stephen Benkovic at Pennsylvania State University
  • Entered into a $21.6 million contract with the Department of Defense to explore the use of boron chemistry in biodefense


  • Explored potential uses of boron in drug development and generated data showing that boron platform had potential applications in a variety of diseases including bacterial, fungal, viral, and parasitic infections as well as inflammatory diseases


  • First compound entered clinical trials


  • Neglected Diseases
    • Entered into agreements with the Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) to apply our boron chemistry platform in the area of neglected diseases


  • Kerydin
    • Initiated Phase 3 trial for mild-to-moderate onychomycosis
  • AN3365 (GSK ‘052)
    • Reported Phase 1 results showing that AN3365 appeared to be safe and well-tolerated, after which GSK exercised its option to obtain an exclusive license to develop and commercialize AN3365. Upon exercise of the option, Anacor received a fee of $15.0 million
  • Entered into a research agreement with Eli Lilly and Company, or Lilly, to discover products for a variety of animal health applications
  • Neglected Diseases
    • Entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) develop new therapeutics for the treatment of malaria
    • Entered research and development collaboration agreement with UCSF's Sandler Center to discover new drug therapies to treat River Blindness
  • Completed Initial Public Offering


  • AN2728
    • Completed  successful End of Phase 2 meeting with the FDA for AN2728 in mild-to-moderate psoriasis and received Special Protocol Assessment (SPA) on major parameters of Phase 3 trial design of AN2728 in mild-to-moderate psoriasis.
  • AN2728 and AN2898
    • Successfully completed Phase 2a trial in mild-to-moderate atopic dermatitis
  • AN3365
    • GSK initiated two Phase 2 trials in complicated urinary tract infections and complicated intra-abdominal infections


  • Neglected Diseases
    • DNDi initiated a Phase 1 study of AN5568 for HAT in France.


  • Kerydin
    • Announced positive results from two Phase 3 studies of Kerydin for the treatment of mild-to-moderate onychomycosis
    • New Drug Application (NDA) accepted by the U.S. Food and Drug Administration (FDA) for review
  • AN2728
    • Completed third Phase 2 study of AN2728 in mild-to-moderate atopic dermatitis
  • Neglected Diseases
    • Signed $17.7 million research agreement with the Bill & Melinda Gates Foundation and received $5 million investment in common stock
  • Received $142.5 million from Valeant Pharmaceuticals to settle disputes related to Dow Pharmaceutical Sciences and Medicis Pharmaceutical Corporation


  • AN2728
    • Held successful End of Phase 2 meeting with the FDA for AN2728 in the treatment of mild-to-moderate atopic dermatitis
    • Initiated Phase 3 trials of AN2728 in mild-to-moderate atopic dermatitis

Our objective is to discover, develop and commercialize proprietary boron-based drug compounds with superior efficacy, safety and convenience for the treatment of a variety of diseases. The key elements of our strategy to achieve this objective are to:

  • Drive rapid, efficient discovery of novel boron-based compounds. We believe the unique characteristics of boron and the expertise we have developed allow us to design novel product candidates that target a broad range of diseases and drive a rapid and efficient drug development process. We have discovered and advanced seven compounds into development in ten years and, in addition, have other active and ongoing research and development programs.
  • Focus development activities in our core therapeutic areas. We intend to focus our development activities in our core therapeutic areas of fungal, inflammatory and bacterial diseases. To fully leverage our boron chemistry platform, we have established and will continue to pursue development partnerships in these therapeutic areas.
  • Commercialize our products ourselves in specialty markets in the United States. We intend to build a sales force to focus on domestic specialty markets, such as dermatology. We have entered into and will continue to seek commercialization partners for products in non-specialty and international markets.
  • Leverage partnerships for non-core therapeutic areas. We believe boron chemistry has utility in a broad range of diseases outside of our core therapeutic areas. To maximize the value of our boron chemistry platform and to provide non-dilutive capital to support development in our core therapeutic areas, we have entered into and will continue to seek partnerships early in development for compounds in non-core areas, such as parasitic, cancer and ophthalmic indications and for applications in animal health.
  • Expand and protect our intellectual property. We intend to expand and aggressively prosecute our intellectual property in the area of boron chemistry and boron-based compounds. Since a relatively limited amount of research has been done in the area of boron-based drug development, we believe that we can establish a defensible and valuable intellectual property portfolio.